TRDA - Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
- Entrada Therapeutics press release ( NASDAQ: TRDA ): Q2 GAAP EPS of -$0.74 misses by $0.02 .
- Cash, cash equivalents and marketable securities were $244.3 million as of June 30, 2022, compared to $291.1 million as of December 31, 2021.
For further details see:
Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02